Regentis Biomaterials

What Regentis Biomaterials does

Regentis Biomaterials Ltd. is an Israeli regenerative medicine company developing and commercializing proprietary hydrogel implants for tissue repair, with a primary focus on focal articular knee cartilage damage. The company's lead product, GelrinC, is a cell-free, off-the-shelf hydrogel implant based on the Gelrin platform — a patented matrix of polyethylene glycol diacrylate crosslinked with denatured fibrinogen, originally developed at the Technion - Israel Institute of Technology by Prof. Dror Seliktar. GelrinC is applied as a liquid that fills the cartilage defect and is cured in-situ with UV light into a rubbery implant, which then degrades by controlled surface erosion over 6-9 months and is replaced by hyaline cartilage. The asset carries CE Mark approval in Europe, where Regentis is now establishing a Centers of Excellence network anchored by Humanitas Research Hospital in Milan, while in the U.S. it is advancing a pivotal FDA Phase III trial that has surpassed 50% enrollment.

The company is publicly traded on NYSE American under the ticker RGNT following a December 2025 IPO that raised $10 million, with a subsequent $6.5 million private placement priced in June 2026. Regentis monetizes GelrinC through direct enterprise sales to orthopedic surgeons at academic medical centers and hospitals, targeting a $3 billion U.S. addressable market and approximately 470,000 annual U.S. knee cartilage repair cases where no FDA-approved off-the-shelf regenerative solution exists. The platform is protected by 35 issued patents worldwide (9 in the U.S.), including a new U.S. patent granted December 2025 providing protection through 2038, and the company has developed a proprietary solvent-free manufacturing process that increases production yield by 400%.

Operationally, Regentis is a pre-revenue, development-stage medical device company of 11-50 employees headquartered in Herzlia Pituach, Israel. It is transitioning from clinical development to commercialization under a leadership team that includes CFO/CBO Ori Gon and CMO Dr. Galit Reske (latter with prior FDA approval experience on CartiHeal's Agili-C). Commercial milestones include European surgeon training beginning in Q3 2026, ongoing FDA pivotal trial enrollment, and capital raising to fund PMA submission and market entry; the company's 2025 audit contained a going-concern qualification, underscoring execution and funding risk alongside the clinical and commercial opportunity.

Name

Regentis Biomaterials

Legal name

Regentis Biomaterials Ltd.

Website

https://regentis.co.il

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Regentis Biomaterials is an Israeli regenerative medicine company developing GelrinC, a cell-free, off-the-shelf hydrogel implant for focal knee cartilage repair. It serves orthopedic surgeons and hospitals, with CE Mark approval in Europe and an ongoing FDA pivotal Phase III trial in the United States.

Ownership category

akta.pro rank

Product category

Orthopedic Regenerative Medicine

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

akta.pro secondary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

Keywords

• Regenerative medicine
• Hydrogel implants
• Cartilage repair
• Orthopedic medical devices
• Tissue engineering

Headquarters

HQ city

Or Akiva

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Others

Revenue model

1. Product Sales - GelrinC: Revenue will be generated from direct sales of GelrinC implants to hospitals and orthopedic surgery centers. The company plans to commercialize in Europe following CE Mark approval, with future U.S. market entry pending FDA PMA approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Regentis Biomaterials develops and commercializes the Gelrin hydrogel platform, with its lead product GelrinC being a cell-free, off-the-shelf hydrogel implant for the treatment of painful injuries to articular knee cartilage. The implant is applied as a liquid and cured in-situ with UV light, degrading over 6-9 months and being replaced with healthy hyalin cartilage. GelrinC is CE Mark-approved in Europe and is in a pivotal FDA Phase III trial in the United States.

Product overview

Regentis Biomaterials is a tissue repair company focused on developing and commercializing an innovative hydrogel platform for the repair of damaged tissue. The company's core offering consists of the Gelrin Technology Platform and its lead product GelrinC. GelrinC is a cell-free, off-the-shelf hydrogel implant for knee cartilage repair that has received CE Mark approval in Europe and is currently undergoing pivotal FDA clinical trials in the United States. The Gelrin platform serves as the underlying technology foundation from which GelrinC is derived, utilizing a degradable hydrogel implant to regenerate damaged or diseased tissue.

Differentiator

Problem solved

Functional benefit

Brands

• GelrinC: Cell-free, off-the-shelf hydrogel implant for knee cartilage repair. CE Mark approved in EU; in pivotal FDA trial in US.
• Gelrin

Products and services

• GelrinC Cell-free, off-the-shelf hydrogel implant cured in-situ with UV light in the knee for treatment of painful injuries to articular knee cartilage. The implant degrades within 6-9 months and is replaced with healthy hyalin cartilage tissue. CE Mark approved in Europe and in pivotal FDA Phase III clinical trial in the United States. Target customers are orthopedic surgeons and hospitals.
• Gelrin Technology Platform Hydrogel platform technology composed of polyethylene glycol diacrylate polymer crosslinked with denatured fibrinogen, applied as a liquid and cured in-situ with UV light. Provides controlled gradual surface degradation for tissue regeneration applications. Serves as the underlying technology foundation for Regentis' product portfolio.

Quantifiable outcome

• 100% greater improvement in KOOS and VAS pain scores compared to microfracture surgery over 2-year follow-up in pilot study
• +3 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered flagship and core.

• Humanitas Research HospitalflagshipStrategic or Co-development Partner · 16 April 2026Collaboration with Humanitas Research Hospital in Milan, Italy to support European clinical adoption and commercialization of GelrinC. The partnership establishes a network of European Centers of Excellence to provide surgeon education, clinical guidance, and professional training. First training sessions scheduled Q3 2026.
• Prof. Elizaveta KoncoreStrategic or Co-development Partner · 16 April 2026Renowned cartilage repair expert Prof. Elizaveta Kon collaborating with Regentis and Humanitas to support European clinical adoption of GelrinC.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• CartiHeal (Smith+Nephew): CartiHeal developed Agili-C, a cell-based implant for cartilage repair that recently received FDA approval and was acquired by Smith+Nephew for $330 million. It is the closest direct competitor to GelrinC in indication, mechanism category, and regulatory pathway.
• Vericel: Vericel markets MACI, an autologous cultured chondrocyte implant for knee cartilage repair. It directly competes with GelrinC for the same orthopedic cartilage defect patient population and serves the same surgeon specialty.
• Anika Therapeutics: Anika develops hyaluronic acid-based regenerative therapies for orthopedic applications, including cartilage repair and joint preservation. It overlaps with Regentis's tissue regeneration focus and orthopedic end-market.

Broad incumbents

• Smith+Nephew: Global orthopedic medical device incumbent that owns the Agili-C franchise and competes broadly in sports medicine and cartilage repair. Its acquisition of CartiHeal makes it the most strategically relevant incumbent against Regentis.
• Stryker: Major orthopedic medical device company with sports medicine and joint preservation portfolios. While not focused on regenerative cartilage repair, it represents a potential strategic acquirer and a benchmark competitor in the orthopedic surgical space.
• Zimmer Biomet: Global leader in orthopedic reconstruction and sports medicine, including cartilage repair solutions. Comparable as a broad incumbent with overlapping surgical customers and a likely strategic acquirer for novel cartilage technologies.
• Arthrex: Privately held orthopedic sports medicine leader with a broad portfolio including cartilage repair procedures and biologics. Overlaps with Regentis on surgical customer base and cartilage indications.
• Bioventus: Orthopedic biologics company offering cartilage-related therapies and joint preservation products. Comparable as an incumbent focused on biologics-adjacent solutions for similar orthopedic end-users.

Emerging players

• MiMedx: Regenerative medicine company developing placental tissue-based implants for wound healing and orthopedic applications. Comparable as a smaller, emerging regenerative medicine player pursuing biologic implant commercialization.
• Osiris Therapeutics (Smith+Nephew): Developer of placental and bone-marrow-derived regenerative products for orthopedic and wound healing applications, now part of Smith+Nephew. Overlaps with Regentis on regenerative matrices and biologic implant mechanisms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/regentis-biomaterials-ltd-

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds6 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regentis Biomaterials